Lactobacilli: Blocking HIV/HSV by Mannose Binding
Lactobacilli: Blocking HIV/HSV by Mannose Binding
批准号:
7001990
负责人:
LIN TAO
金额:
$48.87万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-01 至 2010-06-30
关键词:
AlphaherpesvirinaeLactobacillusantiinfective agentsbacterial geneticsbacterial proteinsbinding proteinsbiotechnologybiotherapeutic agentcarbohydrate metabolismclinical researchcooperative studydrug design /synthesis /productionfemalehuman immunodeficiency viruslaboratory mouselaboratory rabbitlaboratory ratlectinmannosemicroorganism interactionsexually transmitted diseasestissue /cell culturetopical drug applicationvirus envelope
中文摘要
描述(由申请人提供):人类免疫缺陷病毒(HIV)和单纯疱疹病毒(HSV)导致显着的发病率和死亡率。虽然这两种病毒都可以通过性传播,但患有生殖器疱疹的人更容易感染艾滋病毒。避孕套提供了极好的保护,但由于依从性差,效果有限。供女性使用的替代预防措施,例如杀微生物剂,是可取的。 HIV是RNA病毒,HSV是DNA病毒,但它们都有高甘露糖的包膜。巧合的是,某些乳杆菌通过特定的结合蛋白依赖性糖摄取系统自然地捕获甘露糖作为首选营养物质。其糖结合蛋白(凝集素)结合甘露糖。通过对近1000个口腔和阴道菌株中的此类凝集素进行筛选,我们从口腔乳杆菌中筛选出2株,从阴道乳杆菌中筛选出5株能够捕获并代谢HIV/HSV包膜甘露糖的菌株。因此,我们建议开发一种基于乳杆菌甘露糖结合凝集素(LMBL)的益生菌杀微生物剂,同时对抗 HIV 和 HSV。我们假设 LMBL 乳杆菌可以通过甘露糖特异性结合来阻断 HIV 和 HSV 感染。该项目旨在进行临床前研究。我们将追求五个具体目标:(1)候选 LMBL 乳杆菌的表型和基因型分析; (2) 记录了 LMBL 乳杆菌在体外对 HSV-2 和 HIV-1 的阻断作用; (3)在小鼠疱疹模型中测试LMBL乳杆菌的体内抗HSV-2功效; (4)评估LMBL乳杆菌在兔和大鼠体内的安全性; (5)优化益生菌杀微生物剂的配方、包装和保质期。这项研究完成后,我们将获得临床前数据并为临床试验做好准备。这种方法的公认优点包括安全性、持久保护和成本效益。优于所有其他杀菌剂,新方法可以不依赖于合规性。它可以不引人注意、不引人注意地保护女性。我们的长期目标是开发一种生物预防方法,作为疫苗或物理屏障的替代品或补充,以保护妇女免受艾滋病毒和单纯疱疹病毒的性传播。我们建议开发一种新方法来对抗艾滋病和疱疹病毒及其天敌。我们分离出了一组友好的乳酸杆菌,它们可以捕获病毒以获取糖分,从而杀死病毒,就像猫捕捉老鼠一样。这种方法的成功开发可能会遏制全球艾滋病毒/单纯疱疹病毒的流行,并最终挽救许多生命。
英文摘要
DESCRIPTION (provided by applicant): The human immunodeficiency virus (HIV) and herpes simplex virus (HSV) cause significant morbidity and mortality. While both viruses can be transmitted sexually, people with genital herpes are more prone to HIV. Condoms offer excellent protection, but the effect has been limited due to poor compliance. Alternative prophylaxis, such as microbicides, for use by women are desirable. HIV is an RNA virus, while HSV is a DNA virus, but they both have an envelope with high mannose. Coincidentally, certain lactobacilli naturally capture mannose as a preferred nutrient by a specific binding protein-dependent sugar uptake system. Its sugar-binding protein (lectin) binds mannose. By screening nearly 1,000 oral and vaginal strains for such lectin, we have selected two strains from oral and five from vaginal lactobacilli that can capture and metabolize envelope mannose of HIV/HSV. Therefore, we propose to develop a probiotic microbicide against both HIV and HSV based on Lactobacillus mannose-binding lectin (LMBL). We hypothesize that LMBL+ lactobacilli can block both HIV and HSV infections by mannose-specific binding. This project is to perform preclinical studies. We will pursue five specific aims: (1) phenotypic and genotypic analyses of candidate LMBL+ lactobacilli; (2) document blockage of LMBL+ lactobacilli against HSV-2 and HIV-1 in vitro; (3) test anti-HSV-2 efficacy of LMBL+ lactobacilli in vivo in a mouse herpes model; (4) assess safety of LMBL+ lactobacilli in vivo in rabbits and rats; and (5) optimize formulation, packaging, and shelf life of the probiotic microbicide. Upon completion of this study, we will achieve preclinical data and be ready for clinical trials. Putative advantages of this method include safety, persistent protection and cost-efficiency. Superior to all other, microbicides, the new method can be compliance-independent. It can protect women unobtrusively and inconspicuously. Our long-term goal is to develop a bio-prophylaxis that can serve as an alternative or supplement to vaccines or physical barriers to protect women against sexual transmission of HIV and HSV. We propose to develop a novel method to fight AIDS and herpes viruses with their natural enemies. We have isolated a group of friendly lactobacilli, which can capture viruses for their sugar, thereby killing the virus, much like cats catching mice. Successful development of this method will likely curb the global HIV/HSV pandemic and ultimately save many lives.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ethanol metabolizing Lactobacillus for cancer prevention
-
批准号:8463146
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2012
-
负责人:LIN TAO
-
依托单位:
Ethanol metabolizing Lactobacillus for cancer prevention
-
批准号:8305927
-
项目类别:
-
资助金额:$7.97万
-
财政年份:2012
-
负责人:LIN TAO
-
依托单位:
Lactobacilli: Blocking HIV/HSV by Mannose Binding
-
批准号:7456591
-
项目类别:
-
资助金额:$49.09万
-
财政年份:2005
-
负责人:LIN TAO
-
依托单位:
Lactobacilli: Blocking HIV/HSV by Mannose Binding
-
批准号:7087939
-
项目类别:
-
资助金额:$48.56万
-
财政年份:2005
-
负责人:LIN TAO
-
依托单位:
Lactobacilli: Blocking HIV/HSV by Mannose Binding
-
批准号:7254853
-
项目类别:
-
资助金额:$48.6万
-
财政年份:2005
-
负责人:LIN TAO
-
依托单位:
Lactobacilli: Blocking HIV/HSV by Mannose Binding
-
批准号:7647120
-
项目类别:
-
资助金额:$50.5万
-
财政年份:2005
-
负责人:LIN TAO
-
依托单位:
Blocking Milk-Borne HIV by Commensal Bacteria
-
批准号:6772447
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2003
-
负责人:LIN TAO
-
依托单位:
Viral Infection in Lactobacilli: An Animal BV Model
-
批准号:6602052
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2003
-
负责人:LIN TAO
-
依托单位:
Viral Infection in Lactobacilli: An Animal BV Model
-
批准号:6718451
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2003
-
负责人:LIN TAO
-
依托单位:
Blocking Milk-Borne HIV by Commensal Bacteria
-
批准号:6695779
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2003
-
负责人:LIN TAO
-
依托单位:
Lactobacilli: A Vaccine Delivery Vehicle for Women
-
批准号:6408818
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2001
-
负责人:LIN TAO
-
依托单位:
Lactobacilli: A Vaccine Delivery Vehicle for Women
-
批准号:6534364
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2001
-
负责人:LIN TAO
-
依托单位:
LACTOBACILLI--A VACCINE DELIVERY VEHICLE FOR WOMEN
-
批准号:2852914
-
项目类别:
-
资助金额:$7.77万
-
财政年份:1998
-
负责人:LIN TAO
-
依托单位:
LACTOBACILLI--A VACCINE DELIVERY VEHICLE FOR WOMEN
-
批准号:2887962
-
项目类别:
-
资助金额:$7.77万
-
财政年份:1998
-
负责人:LIN TAO
-
依托单位:
LACTOBACILLI--A VACCINE DELIVERY VEHICLE FOR WOMEN
-
批准号:6171099
-
项目类别:
-
资助金额:$7.77万
-
财政年份:1998
-
负责人:LIN TAO
-
依托单位:
COORDINATION OF S MUTANS SUCROSE METABOLISM
-
批准号:2634141
-
项目类别:
-
资助金额:$9.86万
-
财政年份:1997
-
负责人:LIN TAO
-
依托单位:
COORDINATION OF S MUTANS SUCROSE METABOLISM
-
批准号:2015173
-
项目类别:
-
资助金额:$10.15万
-
财政年份:1997
-
负责人:LIN TAO
-
依托单位:
COORDINATION OF S MUTANS SUCROSE METABOLISM
-
批准号:2856653
-
项目类别:
-
资助金额:$10.79万
-
财政年份:1997
-
负责人:LIN TAO
-
依托单位:
COORDINATION OF S MUTANS SUCROSE METABOLISM
-
批准号:6342389
-
项目类别:
-
资助金额:$11.18万
-
财政年份:1997
-
负责人:LIN TAO
-
依托单位:
COORDINATION OF S MUTANS SUCROSE METABOLISM
-
批准号:6137919
-
项目类别:
-
资助金额:$10.95万
-
财政年份:1997
-
负责人:LIN TAO
-
依托单位:
国内基金
海外基金
登录
查看更多内容
瘤内细菌 Lactobacillus iners 通过
eIF4A2 乳酸化介导肿瘤相关巨噬细胞极
化诱导膀胱癌免疫化疗抵抗的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:吴志明
-
依托单位:
肠道菌群Lactobacillus来源的吲哚-3-
甲醛对绝经后骨量丢失的保护机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:庄景燊
-
依托单位:
Lactobacillus reuteri调控FTO/CMPK2/NLRP3信号轴介导炎症反应治疗5-FU诱导的口腔粘膜炎的作用研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:邱敬诚
-
依托单位:
葛根交泰丸调控Lactobacillus介导胆汁酸“肠-肝轴”途径治疗2型糖尿病的机制研究
-
批准号:82305009
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:王文波
-
依托单位:
草苁蓉介导的肠道Lactobacillus reuteri菌通过长链脂肪酸调控糖脂代谢改善2型糖尿病的作用机制
-
批准号:32260026
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:全林虎
-
依托单位:
Lactobacillus plantarum CQPC05通过细胞凋亡通路干预结直肠癌的效果
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:余婷
-
依托单位:
基于肠道菌群-免疫轴解析Lactobacillus murinus 0516抗鸡传染性支气管炎病毒感染的机制
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:尹海畅
-
依托单位:
荔枝黄酮QRR与原花青素A2协同增殖肠道Akkermansia和Lactobacillus菌保护肠粘膜屏障机理研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:苏东晓
-
依托单位:
猪肠道细菌Lactobacillus gasseri LA39调控胆汁酸代谢的研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:
-
依托单位:
益生菌Lactobacillus plantarum HNU082在宿主肠道内适应性进化机制研究
-
批准号:32160545
-
项目类别:地区科学基金项目
-
资助金额:36万元
-
批准年份:2021
-
负责人:张家超
-
依托单位: